AZ may spin off its Chinese business, says report

AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t

Henlius Biotech shrugs off Hong Kong disruption with $477M I...

Hong Kong biotechs IPOs face lower valuations after Ascletis...

Biotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after Chinese pioneer Ascletis Pharma’s shares plunged nearly 45% in the first month

Regulatory timelines in the Asia-Pacific

Snapshot of clinical trial application processes in the region.